Berlex Fellowship Open

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

DUMONT, NJ--The Berlex Oncology Foundation is accepting applications until January 6, 1997, for a 2-year clinical research training program open to academically oriented physicians specializing in oncology. The intent is to encourage careers in clinical cancer research. For more information, contact Svetlana Lisanti, Berlex Oncology Foundation, 80 W. Madison Ave., Dumont, NJ 07628; or call 201-385-0006.

DUMONT, NJ--The Berlex Oncology Foundation is accepting applicationsuntil January 6, 1997, for a 2-year clinical research trainingprogram open to academically oriented physicians specializingin oncology. The intent is to encourage careers in clinical cancerresearch. For more information, contact Svetlana Lisanti, BerlexOncology Foundation, 80 W. Madison Ave., Dumont, NJ 07628; orcall 201-385-0006.

Articles in this issue
Routine Office Endometrial Biopsies and Ultrasound Screening Are Not Recommended for Breast Cancer Patients Receiving Tamoxifen
AHCPR to Fund Analysis of the Impact of Managed Care's Growth
Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Women
ASTRO Honors Two Members With Gold Medal and Bestows Honorary Memberships on Two
Friends of Cancer Research Campaign
Four Cancer Chemoprevention Trials Seek Subjects
Overall US Cancer Mortality Rate Falls for the First Time
Four Scenarios Describe Impact of Cancer Research in 2015
New Edition of NABCO Breast Cancer Resource List Is Now Available
Changes in Congressional Committee Chairmen Could Impact Oncologists
Growth Factor in Elderly ALL Patients Improves Outcome
Human Genetic Map Goes On-Line
Study to Explore Smoking Cessation After a Cancer Diagnosis
Novantrone Gets FDA Nod for Use in Advanced Prostate Cancer
New Cancer Programs, Office of Cancer Survivorship Announced
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients

13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients

Amanda Reynolds;Jonathan Klein;Joshua Feinberg;Bayle Smith-Salzberg;Pasang Sherpa;Vijaya Natarajan;Fleure Gallant;Ashley Anderson;Mukuhi Ng’ang’a
July 4th 2025
Article
Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Diagnosing and Treating Patients With Epithelioid Sarcoma

ONCOLOGY Staff
July 4th 2025
Article

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Busulfan-Enhanced VRD Regimen Improves Efficacy in NDMM

Roman Fabbricatore
July 3rd 2025
Article

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Russ Conroy
July 3rd 2025
Article

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.